Table 1 Characteristics of included studies
From: Antibiotic prophylaxis in primary and revision shoulder replacement: a systematic review
Author | Year | Study design (Oxford Center of EBM level) | Population | Patients with ATB therapy | Shoulder Involved | Age (mean) | Gender (m/f) | Microorganism | Type of infection (a/c) * | Time of follow up | Antibiotic |
|---|---|---|---|---|---|---|---|---|---|---|---|
Pérez-Prieto[19] | 2016 | Prospective randomized and controlled study (I) | 28 | 28 | 3 | 74 | 15/13 | A = 14; C = 14 | Cefalosporin Glycopeptide | ||
Kong Koh,[20] | 2016 | Randomized study (I) | 30 | 30 | 30 | 74 | 7/23 | P. acnes | 9- months | Cefazolin Gentamicin | |
Lutz[21] | 2005 | Retrospective study II | 52 | 35 | 15 | 51,8 | 37/15 | P. acnes | average follow-up 37.1 months | Clindamycin–Ofloxacin (n = 14PZ) Rifampicin–Ofloxacin(n = 6PZ) Clindamycin–Rifampicin (n = 3PZ) Cloxacillin–Ofloxacin(n = 2) Rrifampicin–Pristinamycin (n = 2PZ) Ceftriaxone–pristinamycin(n = 1PZ) Cefepime–Ofloxacin (n = 1PZ) eicoplanin–Rifampicin (n = 1PZ) Clindamycin–Fusidic Acid (n = 1PZ) Clindamycin monotherapy(n = 1PZ) Vancomycin–Ceftazidime–Ciprofloxacin(n = 1PZ) | |
Opric a[22] | 2004 | Retrospective study (II) | 328 | 304 | 304 | P. acnes | Clindamycin Erythromycin Tetracycline Linezolyd Benzypenicillin Vancomycin | ||||
Matse n[23] | 2015 | Prospective study (I) | 10 | 10 | 10 | range 11–58 | 10/0 | P. acnes | Ceftriaxone Vancomycin | ||
Parad a[24] | 2018 | An on-line survey (V) | 84 | 62 | 62 | P. acnes | Cefazolin Vancomicin Clindamycin | ||||
Al-Mayahi[25] | 2015 | Case-control study (III) | 2740 | 1167 | 2740 | 57 | S. aureus | Quinolone Beta-Lactam Long-Acting Agent (Vancomycin, Teicoplanin, Ceftriaxone, Ertapenem) |